Can BioAtla’s Oz-V set a new standard in ROR2-targeted therapy for head and neck cancer?
BioAtla and GATC Health advance Ozuriftamab Vedotin into a Phase 3 trial for OPSCC via SPV financing. Discover how this targets cancer and aging together.
Meta-Flux and Mercury Bio team up to target intracellular CNS pathways with precision
Mercury Bio Inc., a biotechnology company focused on large-molecule therapeutics, has announced a strategic collaboration with Meta-Flux, a disease simulation company that leverages artificial intelligence, to advance drug discovery programs for Parkinson’s disease and Alzheimer’s disease. The partnership combines Mercury Bio’s proprietary yeast extracellular vesicle (yEV) delivery technology with Meta-Flux’s disease-scale computational modeling platform, with […]